about
Quality of life in patients with psoriasisComplementary therapies for chronic plaque psoriasisTriptolide in the treatment of psoriasis and other immune-mediated inflammatory diseasesTargeting of interleukin-17 in the treatment of psoriasisSecukinumab: A New Treatment Option for Psoriatic ArthritisCo-morbidity in psoriasis: mechanisms and implications for treatment.Rationale and early clinical data on IL-17 blockade in psoriasis.Psoriasis causes significant economic burden to patients.Serum fatty acid profile in psoriasis and its comorbidity.Treatment costs of psoriasis in a tertiary-level clinic.Comparison of MHC class I risk haplotypes in Thai and Caucasian psoriatics shows locus heterogeneity at PSORS1The coexistence of psoriasis and vitiligo: a review.Targeted phototherapy using 308 nm Xecl monochromatic excimer laser for psoriasis at difficult to treat sites.Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case-control study.Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances.Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review.Genetic Epidemiology of PsoriasisAlkyloxy carbonyl modified hexapeptides as a high affinity compounds for Wnt5A protein in the treatment of psoriasis.Alpha-1 antitrypsin, retinol binding protein and keratin 10 alterations in patients with psoriasis vulgaris, a proteomic approach.Allele-specific network reveals combinatorial interaction that transcends small effects in psoriasis GWAS.Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis--xenograft modelSerum levels of 25-hydroxy vitamin D in psoriatic patients.The MARCOPOLO Study of Ustekinumab Utilization and Efficacy in a Real-World Setting: Treatment of Patients with Plaque Psoriasis in Asia-Pacific Countries.Pathway Analysis of Skin from Psoriasis Patients after Adalimumab Treatment Reveals New Early Events in the Anti-Inflammatory Mechanism of Anti-TNF-αQuality of life and psychosocial aspects in Greek patients with psoriasis: a cross-sectional study.Inverse psoriasis involving genital skin folds: successful therapy with dapsoneA Rare Clinical Presentation of Giant Bilateral Labial Fibroepithelial Stromal Polyps in Patient with Psoriasis Disease.The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder.Psoriasis aggravation due to lapatinibSecukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trialDeveloping a diagnostic checklist of traditional Chinese medicine symptoms and signs for psoriasis: a Delphi studyFeasibility of establishing deletion of the late cornified envelope genes LCE3B and LCE3C as a susceptibility factor for psoriasisA statistical analysis plan for the efficiency and safety of Chinese herbal medicine used concurrently with topical therapy for psoriasis vulgaris.The costs of psoriasis medications.Combination Therapy of Etanercept and Fumarates versus Etanercept Monotherapy in Psoriasis: A Randomized Exploratory Study.Increase in circulating sphingosine-1-phosphate and decrease in ceramide levels in psoriatic patients.A study of the use of drugs in patients suffering from psoriasis and their impact on quality of lifeEfficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.Current understanding of human genetics and genetic analysis of psoriasis.Role of IL-17 in psoriasis and psoriatic arthritis.
P2860
Q21245617-627C30AC-9D51-4298-82E7-1123BE984388Q24194968-42C53599-09AF-4B5E-8843-D0E1A34B25C0Q24626931-2BE50B4E-82E0-4DAA-8095-67C7D2FE9ADFQ27026324-572AFB69-A99B-41CD-BF8E-94759816FDBDQ28066204-2E183869-3116-46B0-808E-EDE8623AC235Q30248952-DFB6D59F-1F78-4EFD-A250-420E4B154CFDQ30658185-7B3EF1FB-32CC-437F-B381-6BA2E75C10F0Q33785034-94225781-09CC-42F6-B971-F00AFB14A8A8Q33840850-11AE28D8-CD62-4469-AC9F-B46ED8DCF885Q34076641-4661EEC5-E0D7-4B30-A296-7A0C6EE847E4Q34268080-F8AD3F2A-9DF1-4F3B-8E4E-480CCCC56393Q34413260-DD47504F-F63C-41BD-93F2-36717875E124Q34439924-3360DF4D-FB22-43F1-A545-82B1127E6235Q34590463-79516E66-A9DF-4F9F-ADB8-438334428CB8Q34631384-682BAB20-8DB9-40B2-8360-2E164040C320Q34812877-C14AE3E6-E53F-4224-AA27-2A6D9102D8A7Q34845927-EBB29A99-DE93-4E59-9808-5EEA7B53B63DQ35033149-7D218B99-32E2-4EDA-BA22-E8DDBD9AE49FQ35065155-04BD96AA-C677-4A0D-B74A-8859E49E63B8Q35261257-F8961490-2816-44DA-8C42-5F75BABB33D0Q35429501-ACCB257C-DA30-4AC2-A87D-C464094B8F26Q35892163-31EC6BCF-1F53-44CC-8CF2-AE76763F158DQ35990756-E809C33F-46AE-4E6C-9A70-E71AD2B30F2FQ36231590-5ED07EDB-3544-41F4-B976-27A2463380A1Q36398293-8147A828-CAE3-4FA9-B8CB-15640329F7A5Q36434768-41B22F86-E2B2-4580-A3BB-57616F292678Q36559259-5ECB39E4-0E6B-4896-9489-BAE4A29494C8Q36653650-E26B53FF-0481-454E-8614-060B338F964CQ36704672-088FBB8E-9FD2-4AAF-B916-FAC9251CCDDEQ36746549-BFE5BF53-E3A7-490A-B478-FF5783A044FBQ36863477-DD01EAFF-A466-4EF8-BB89-E773BA962535Q37031620-7418C871-423C-4908-BC40-986820B5CDE7Q37307635-0A3DFC0F-EE4F-4FB9-B325-316DE8E2B1ACQ37468355-193F9C63-8752-473F-BB01-AE769E83B51AQ37630778-FA1C5E8F-1F10-4C5A-B300-7AB9D7F23069Q37642111-73CB01C4-B4F7-4C42-9115-4353D1EE3A91Q37701023-41746D78-B28E-4E9F-8717-608F5B65AC2FQ37743492-2B51E98F-382F-4232-AAE8-CB6AA988707BQ37986834-1B9E6863-9607-4B0B-90E8-9B514AE73D6FQ37987880-3F34120E-55AC-4225-9DDA-AF2214B03B56
P2860
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
The prevalence of psoriasis in the world.
@en
The prevalence of psoriasis in the world.
@nl
type
label
The prevalence of psoriasis in the world.
@en
The prevalence of psoriasis in the world.
@nl
prefLabel
The prevalence of psoriasis in the world.
@en
The prevalence of psoriasis in the world.
@nl
P1476
The prevalence of psoriasis in the world.
@en
P2093
Raychaudhuri SP
P356
10.1046/J.1468-3083.2001.00192.X
P577
2001-01-01T00:00:00Z